Latest news with #LifeStanceHealth
Yahoo
a day ago
- Business
- Yahoo
UBS Raised the Firm's PT on LifeStance Health Group (LFST), Kept a Buy Rating
LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the . On August 8, UBS raised the firm's price target for LifeStance Health Group, Inc. (NASDAQ:LFST) from $8.50 to $9, while maintaining a Buy rating on the stock. The increased price target follows the company's fiscal second-quarter earnings release. The company exceeded both revenue and earnings estimates during the quarter. LifeStance Health Group, Inc. (NASDAQ:LFST) posted a revenue of $345.31 million, reflecting a 10.56% year-over-year growth and ahead of estimates by $58,730. Moreover, the EPS of negative $0.01 also beat the analyst consensus by $0.02. A close-up of a healthcare professional studying a computer screen with data while consulting with a patient. Management noted that they increased the number of clinicians providing care by 11% year-over-year, which led to a 12% increase in visit volumes during the quarter. Looking ahead, management has reaffirmed its full-year revenue guidance in the range of $1.40 billion to $1.44 billion. LifeStance Health Group, Inc. (NASDAQ:LFST) is a reimagining mental health company that provides both virtual and in-person mental healthcare for children, adolescents, and adults. While we acknowledge the potential of LFST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
LifeStance Health Group (LFST) Reports Q2 Loss, Tops Revenue Estimates
LifeStance Health Group (LFST) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +66.67%. A quarter ago, it was expected that this outpatient mental health services provider would post a loss of $0.04 per share when it actually produced break-even earnings, delivering a surprise of +100%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. LifeStance Health, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $345.31 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.02%. This compares to year-ago revenues of $312.33 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. LifeStance Health shares have lost about 47.1% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for LifeStance Health? While LifeStance Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for LifeStance Health was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $359.78 million in revenues for the coming quarter and -$0.06 on $1.42 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Outpatient and Home Healthcare is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, RadNet (RDNT), has yet to report results for the quarter ended June 2025. The results are expected to be released on August 10. This operator of medical diagnostic imaging centers is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +6.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. RadNet's revenues are expected to be $488.57 million, up 6.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report LifeStance Health Group, Inc. (LFST) : Free Stock Analysis Report RadNet, Inc. (RDNT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 days ago
- Business
- Yahoo
Why LifeStance Health Group (LFST) Stock Is Up Today
What Happened? Shares of behavioral health company LifeStance Health (NASDAQ:LFST) jumped 11% in the afternoon session after the company reported mixed second-quarter 2025 results, delivering an earnings beat and a full-year profit forecast that topped Wall Street estimates. The mental healthcare provider's revenue for the quarter grew 10.6% year-over-year to $345.3 million, which was in line with analyst forecasts, driven by a 10.7% increase in sales volumes. On the bottom line, the company demonstrated improved profitability, posting a GAAP loss of $0.01 per share. This marked a significant improvement from the $0.06 per-share loss in the same period last year and beat consensus estimates for a $0.03 loss. Looking ahead, management provided a full-year Adjusted EBITDA forecast with a midpoint of $145 million, above analyst expectations. However, the company's revenue guidance for the next quarter came in below estimates, creating a mixed picture for investors. Is now the time to buy LifeStance Health Group? Access our full analysis report here, it's free. What Is The Market Telling Us LifeStance Health Group's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. But moves this big are rare even for LifeStance Health Group and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 21 days ago when the stock dropped 4% on the news that several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. LifeStance Health Group is down 42.6% since the beginning of the year, and at $4.33 per share, it is trading 47% below its 52-week high of $8.17 from January 2025. Investors who bought $1,000 worth of LifeStance Health Group's shares at the IPO in June 2021 would now be looking at an investment worth $197.77. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
Yahoo
02-08-2025
- Business
- Yahoo
Lifestance Health Group (LFST) Rated as a Buy at BTIG amid Commercially Insured Patients Boost
LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the penny stocks that will skyrocket. On July 25, BTIG initiated coverage of the stock with a 'Buy' rating and an $8 price target. The bullish stance comes as the research firm maintains that the company is well-positioned to capitalize on its patients who are commercially insured. A healthcare professional using an iPad to help a patient intake process. As one of the nation's largest outpatient mental health providers with 7,500 clinicians across 33 states, the company operates over 550 centers. Last year alone, the company provided care to over 940,000 patients, affirming a firm revenue base. BTIG maintains that Lifestance Health is well-networked into the healthcare system. Therefore, the company remains well-positioned to capitalize on commercial insurance rates, which are typically higher than Medicare and Medicaid rates. 'We like how LFST provides both virtual (70%) and in-person (30%) care with an extensive range of services including the ability to prescribe medications, therapy, psycho-therapy, and advanced treatment options. In our view Lifestance is differentiated from peers because of this thorough, in-person and virtual care model, our channel checks indicate that the therapists usually face high demand, likely due to the referral relationships that LFST has built, and the overall business continues to grow,' BTIG in a research note. LifeStance Health Group, Inc. (NASDAQ:LFST) is a national outpatient mental healthcare platform. It offers a range of services, including therapy, psychiatry, and psychological testing, both in-person and through telehealth. While we acknowledge the potential of LFST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23-07-2025
- Business
- Yahoo
LifeStance Health (LFST) Appoints Vaughn Paunovich as Chief Technology Officer
LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the . On May 14, LifeStance Health Group, Inc. (NASDAQ:LFST) announced appointing Vaughn Paunovich as Chief Technology Officer, effective June 9, 2025. Paunovich will oversee all technology initiatives at LifeStance Health Group, Inc. (NASDAQ:LFST), while strengthening digital platforms for both patients and clinicians. Dave Bourdon, the CEO, praised Paunovich's history of leading top technology teams. He brings over 25 years of experience in health care technology and has previously worked at Amwell as EVP of Enterprise Platforms and held senior technology roles at UnitedHealth Group and Optum Health. A close-up of a healthcare professional studying a computer screen with data while consulting with a patient. LifeStance Health Group, Inc. (NASDAQ:LFST) provides virtual and in-person outpatient mental health care for children, adolescents, and adults. While we acknowledge the potential of LFST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
